FindTrial
Sign In

Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study

Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-003582-16-IT
Enrollment
Unknown
Registered
2007-04-04
Start date
2006-07-11
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women with advanced metastatic breast cancer, not previously treated with anthracyclines or taxanes MedDRA version: 6.1 Level: HLT Classification code 10006292

Interventions

Trade Name: FARMORUBICINA IV FL 200MG100ML Pharmaceutical Form: Solution for infusion INN or Proposed INN: Epirubicin CAS Number: 56390-09-1 Concentration unit: mg milligram(s) Concentration type: equ

Sponsors

AZIENDA OSPEDALIERA POLICLINICO DI MODENA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026